UC San Francisco and Continuum Therapeutics scientists develop promising MS drug PIPE-307 in Phase II trials.
Scientists at UC San Francisco and Contineum Therapeutics have developed a promising drug, PIPE-307, in clinical trials to reverse the effects of Multiple Sclerosis (MS). The drug targets a receptor that prompts brain cells to mature into myelin-producing oligodendrocytes, potentially reversing damage caused by the degenerative disease. PIPE-307 has successfully passed a Phase I trial and is currently in Phase II trials involving MS patients.
August 05, 2024
3 Articles